Skip to main content
Download PDF

Prognostic significance of 18F-Fluorodeoxyglucose positron-emission tomography parameters in patients with biliary tract cancers: a meta-analysis

BMC Medical Imaging volume 24, Article number: 9 (2024) Cite this article

Abstract

Background and objective

Numerous previous studies have assessed the prognostic role of 18F-fluorodeoxyglucose positron-emission tomography (18F FDG PET) in patients with biliary tract cancer (BTC), but those results were inconsistent. The present study aims to determine the predictive value of 18F FDG PET in BTC patients via a meta-analysis.

Methods

The underlying studies related to 18F FDG PET and BTC patients` outcomes were searched and identified in the online databases. The interested parameters include total lesion glycolysis (TLG), metabolic tumor volume (MTV), primary tumor and metastatic lymph node (LN) maximum standardized uptake value (SUVmax), as well as change of SUVmax (ΔSUVmax) during treatment. Overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) were considered as the primary endpoints. Hazard ratio (HR) and corresponding 95% confidence intervals (CIs) were defined as the effective measure and calculated by a pooled analysis. Publication bias was assessed by funnel plot, Bagg’s and Egger’s tests.

Results

Totally, 23 studies involving 1478 patients were included in the present meta-analysis. After a pooled analysis, it revealed that a high SUVmax was significantly associated with a poor OS (HR:2.07, 95%CI: 1.74–2.46, P = 0.000) and DFS (HR: 2.28, 95%CI: 1.53–3.41, P = 0.000). In addition, an increased TLG level contributed to a shorter OS (HR:1.91, 95%CI: 1.26–2.90, P = 0.002) and DFS (HR: 4.34, 95%CI: 1.42–13.27, P = 0.01). Moreover, we confirmed that an elevated MTV was significantly associated with increased mortality (HR:2.04, 95%CI:1.26–3.31, P = 0.004) and disease relapse (HR: 3.88, 95%CI:1.25–12.09, P = 0.019) risks. Besides, the present study uncovered that increased ΔSUVmax could predict poor OS (HR:1.26, 95%CI:1.06–1.50, P = 0.008) instead of PFS (HR: 1.96, 95%CI: 0.82–4.72, P = 0.280). Lastly, we found that LN SUVmax did not link to OS (HR: 1.49, 95%CI: 0.83–2.68, P = 0.178). No obvious publication bias was detected in the present study.

Conclusion

18F FDG PET parameters, including SUVmax, TLG, MTV, and ΔSUVmax, could be applied as convenient and reliable factors for predicting BTC patients` outcomes.

Peer Review reports

Introduction

As a highly heterogeneous disease, biliary tract cancer (BTC), including intrahepatic, perihilar, and distal cholangiocarcinoma, as well as gallbladder and ampulla cancer, is a low-incidence but fatal neoplasm with poor prognosis [1]. The global morbidity of intrahepatic cholangiocarcinoma (ICC) is rising gradually, especially in low-income countries [2]. Despite the application and development of several examination methods and treatment options, patients` overall survival (OS) remains limited [3]. Surgical resection is the primary curative option for early-stage BTC patients. Unfortunately, most patients develop locally advanced or metastatic disease when diagnosed due to a lack of particular symptoms in the early stage. Their survival is restricted, although palliative chemotherapy has been recommended. In addition, most postoperative patients would suffer from disease relapse, which limited their 5-year OS rate to approximately 20–60% [4]. So far, the recurrent and mortality risks of BTC remain less understood. It is essential to explore the underlying prognostic factors to identify the high-risk population in order to achieve precision management.

As an imaging technique based on glucose metabolism to assess a variety of physiological and disease processes, 18F-fluorodeoxyglucose positron-emission tomography (18F FDG PET) has been defined and applied in staging and managing multiple cancers, including BTC. Interestingly, numerous previous meta-analyses determined that some parameters of 18F FDG PET could be utilized as prognostic factors in patients with gastric cancer [5], pancreatic cancer [6], and lung cancer [7] instead of BTC. Meanwhile, the predictive significance of 18F FDG PET parameters has been assessed in BTC by previous clinical studies. However, these results were inconsistent due to different sample sizes and study designs. For example, the cohort studies conducted by Seo et al. [8] and Yho et al. [9] demonstrated that the maximum standardized uptake value (SUVmax) of primary tumor mass was an independent predictor for disease-free survival (DFS) and OS. By contrast, some investigators demonstrated that SUVmax did not contribut to BTC patients` outcomes [10, 11]. Therefore, we performed the present meta-analysis to re-assess the prognostic value of multiple 18F FDG PET parameters, including total lesion glycolysis (TLG), metabolic tumor volume (MTV), primary tumor, and metastatic lymph nodes (LN) SUVmax, as well as change of SUVmax (ΔSUVmax) during treatment in patients with BTC.

Methods

Search strategy

Published studies potentially related to BTC and 18F FDG PET were searched from the PubMed, Embase, Cochrane Library, and Web of Science databases in August 2022. The keywords “biliary tract cancer,” “cholangiocarcinoma,” “positron-emission tomography,” and “prognosis,” as well as related abbreviations, were used for the screening and identification of candidate studies to be included in the meta-analysis. Multiple synonyms were also utilized.

Inclusion and exclusion criteria

Eligible studies were identified using the following criteria: (1) studies addressing the relationship between the outcomes of patients with BTC and metabolic parameters of 18F FDG PET, (2) diagnosis of all BTC participants by pathological examination. (3) reported in English.

The exclusion criteria for this meta-analysis were: (1) other types of articles (i.e., reviews, conference abstracts, case reports, or comments); (2) in vivo or in vitro research studies; (3) lack of data on DFS, PFS or OS; (4) lack of hazard ratios (HRs) and 95% confidence intervals (CIs) as practical measurements; (5) involving other pathological types of cancer patients.

Data management and outcome assessment

According to the above criteria, two investigators independently screened and reviewed available publications through abstract and full-text reading. If there was any disagreement between them, a consensus was reached through discussion with a senior investigator. We collected and defined the HRs and 95% CIs of OS and DFS as the effective measurements. The HRs and 95% CIs calculated by multivariate analysis were preferentially selected for the pooled analysis for better accuracy.

Quality assessment

The evidence level of the studies was estimated by the UK Cochrane Centre of Evidence (2009). Newcastle-Ottawa Scale [12] was utilized to assess the quality of the retrospective cohort studies. The selection of patients, comparability of the study groups, and assessment of outcome represent the critical factors of this scale, with the maximum total score of 9. Studies with scores ≥6 were defined as high-quality studies, and this was a presetting selection criterion in this report.

Statistical analysis

The HRs and associated 95% CIs were calculated to pool the functional outcomes. Statistical heterogeneity among the studies was assessed using chi-square tests with the significance set to P < 0.05 or I2 > 50%. A fixed-effects model was utilized if there was no evident heterogeneity; otherwise, we selected a random-effects model to minimize the heterogeneity, followed by subgroup and sensitivity analysis. Funnel plots, Egger’s, and Begg’s tests were used to examine publication bias. All statistical analyses were performed using STATA version 14.0 (Stata statistical software, College Station, TX, USA).

Results

Characteristics of included studies

After removing duplicated articles (n = 229), 751 studies were identified for review and screening. We excluded 303 unrelated studies, 171 reviews, 65 conference abstracts, 132 case reports, and 9 in vivo or in vitro studies by reading their titles and abstracts. According to the above criteria, 48 studies were excluded after full-text review due to the following reasons: 1) lack of data on OS or DFS (n = 30); 2) including non-biliary tract original cancers (n = 8); lack of HR and relevant 95%CIs (n = 10) (Fig. 1).

Fig. 1
figure 1

Flow of studies selection

Full size image

Totally, this meta-analysis enrolled 23 retrospective cohort studies with 1478 patients with BTC patients, which contains intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), as well as gallbladder and ampullary cancer [8,9,10,11, 13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31]. The level of evidence is 2a. Based on the Newcastle–Ottawa Scale, all studies received a quality score of 6–9. The interested metabolic parameters of 18F-PET/CT included primary tumor maximum standardized uptake value (SUVmax) (n = 19), total lesion glycolysis (TLG) (n = 5), metabolic tumor volume (MTV) (n = 5), lymph nodes SUVmax (n = 2), and change of SUVmax (ΔSUVmax) (n = 3). (Table 1).

Table 1 Characteristics of included studies (n = 23)
Full size table

Prognostic role of primary tumor SUVmax in OS and DFS

Nineteen studies, including 1326 patients, described the relationship between SUVmax of primary tumor and OS. Based on the result of heterogeneity (I2 = 13.8%, P = 0.740), a fixed-effect model was carried out for analysis of these data. It was revealed that an increased SUVmax was significantly associated with a worse OS (HR:2.07, 95%CI: 1.74–2.46, P = 0.000) (Fig. 2A, Table 2). Similarly, a higher SUVmax contributed obviously to a worse DFS (HR: 2.28, 95%CI: 1.53–3.41, P = 0.000) after a pooled analysis of 8 studies with 458 patients using a random-effect model (I2 = 69.5%, P = 0.005) (Fig. 2B, Table 2).

Fig. 2
figure 2

High SUVmax value indictade a poor OS (A) and DFS (B)

Full size image
Table 2 Results of meta-analysis of interested outcomes
Full size table

The predictive value of TLG in OS and DFS

There were 5 studies (including 202 cases) focused on the correction of TLG and OS. After a pooled analysis with a fixed-effect model (I2 = 0.0%, P = 0.484), we found that an increased TLG linked to a higher risk of mortality (HR:1.91, 95%CI: 1.26–2.90, P = 0.002) (Fig. 3A, Table 2). Additionally, 2 studies with 49 patients reported the relationship between TLG and disease recurrence risk. When analyzed with a fixed-effect model (I2 = 0.0%, P = 0.660), it revealed that an increased TLG was obviously associated with poor DFS (HR: 4.34, 95%CI: 1.42–13.27, P = 0.01) (Fig. 3B, Table 2).

Fig. 3
figure 3

Increased TLG level predicted high risk of mortality (A) and disease relapse (B)

Full size image

Prognostic significance of MTV in OS and DFS

Totally, 5 studies involving 202 cases analyzed the relationship between MTV and patients` survival. As the result of pooled analysis with a fixed-effect model (I2 = 8.6%, P = 0.357), it was confirmed that an elevated MTV was significantly associated with worse OS (HR:2.04, 95%CI:1.26–3.31, P = 0.004) (Fig. 4A, Table 2). In addition, we demonstrated that a lower MTV contributed to better DFS significantly (HR: 3.88, 95%CI:1.25–12.09, P = 0.019) when analyzing 2 studies (including 49 cases) using a random-effect model (I2 = 52.1%, P = 0.148) (Fig. 4B, Table 2).

Fig. 4
figure 4

High MTV value contributed to poor OS (A) and DFS (B)

Full size image

Prognostic significance of ΔSUVmax and lymph nodes SUVmax in OS and PFS

Three studies with 136 patients reported the correction of ΔSUVmax and patients` survival. The ΔSUVmax were defined as the changes of SUVmax between pre- and post-treatment. The intervals were about 42 days, 2 months, and 3 months, respectively. After a pooled analysis with a fixed-effect model (I2 = 26.6%, P = 0.256), it demonstrated that an elevated ΔSUVmax was significantly associated with the mortality risk (HR:1.26, 95%CI:1.06–1.50, P = 0.008) (Fig. 5A, Table 2). 2 studies with 110 patients reported the relationship between ΔSUVmax and cancer progression risk. When analyzed with a random-effect model, we found that an increased ΔSUVmax was not associated with PFS (HR: 1.96, 95%CI: 0.82–4.72, P = 0.280) (Fig. 5B, Table 2).

Fig. 5
figure 5

Elevated ΔSUVmax reflected worse OS (A) instead of DFS (B) Lymph node SUVmax could not predicted patients` survival (C)

Full size image

In contrast with primary tumor SUVmax, we found that lymph nodes SUVmax (LN SUVmax) did not contribute to OS (HR: 1.49, 95%CI: 0.83–2.68, P = 0.178) after a pooled analysis on 2 studies (involving 301 cases) with a fixed-effect model (Fig. 5C, Table 2).

Publication bias

Publication bias was examined by Begg’s and Egger’s tests, as well as funnel plots. All P-values obtained from Egger’s and Begg’s tests for each parameter and endpoint were > 0.05 (Table 2). Additionally, the visual inspection of the funnel plots did not show pronounced asymmetry (Fig. 6). These results confirmed the absence of publication bias risk among the included studies in the present meta-analysis.

Fig. 6
figure 6

No publication bias were detected by funnel plots

Full size image

Discussion

Due to different origin sites and cancer biology, the outcomes of BTC patients are heterogeneous [32]. Therefore, the identification of reliable prognostic factors is crucial in an era of precision medicine and helps to understand the risk of disease progression and patients` mortality. The clinical-pathological features, including tumor staging information and demographic factors remain the critical consideration for clinical practice and prognosis. Interestingly, the metabolic parameters of 18F FDG PET may provide important biological information beyond the clinical-pathological characteristics in patients with BTC. Therefore, the predictive role of these parameters must be determined.

The diagnostic and staging significance of 18F FDG PET have been determined by previous meta-analyses [33,34,35]. However, few meta-analysis assessed and reviewed the prognostic value of this novel imaging tool. According to available studies, we performed the present meta-analysis and demonstrated that higher values of SUVmax, MTV, and TLG predicted a higher risk of disease recurrence or death in patients with BTC. In addition, the emerging parameters such as LN SUVmax and ΔSUVmax have also been focused by our study, but the prognostic value needs further investigation due to insufficient published studies. These findings suggest that 18F FDG PET is not only a diagnostic tool but may be used to distinguish BTC patients who are at high risk of tumor recurrence or death and may benefit from subsequent, more aggressive treatments.

SUVmax is the most commonly used parameter in 18F FDG PET diagnosis and response monitoring because of its high reproducibility and availability. FDG uptake can reflect the metabolic activity of the tumor tissue. SUVmax has been shown to correlate with tumor mitotic count and with prognosis in cancer patients [36]. Previous studies demonstrated that the value of SUVmax was associated with multiple clinical-pathological features, including histological grade [37]. In addition, it has been uncovered that SUVmax was significantly correlated with programmed cell death ligand 1 (PD-L1) (P = 0.02) and glucose transporter 1 (GLUT1) (P < 0.01) expression in patients with pulmonary squamous-cell carcinoma [38]. Besides, SUVmax has been revealed as a marker associated with low tumor-infiltrating lymphocyte levels [39]. These results suggested that SUVmax, as a prognostic factor, could reflect cancer immune microenvironment. Interestingly, SUVmax was also associated with tumor tissue hypoxia and angiogenesis, contributing to cancer progression [40, 41].

MTV and TLG, which are a combination of volumetric and metabolic parameters, may be utilized in metabolic analyses of radiotracer activity, reflecting both properties of the tumor tissues. These parameters were also related to angiogenesis [41] and cancer immunity [42]. Taken these considerations, the above parameters in 18F PDF PET were associated to glucose intake, which regards cancer metabolism activity, tumor microenvironment, and immunity. These biological features contribute to tumor growth, cancer relapse, treatment resistance, and metastasis. Thereby, 18F PDF PET could be considered as a prognostic tool in patients with cancer including BTC.

previous studies demonstrated that glycolysis, as metabolic reprogramming, contributed significantly to cholangiocarcinoma initiation and progression [43, 44] Glycolic pathways and enzymes, including pyruvate kinase M2 [45, 46], Aldolase A [47] and lactate dehydrogenase A [48], play a critical role in BTC and have been utilized as biomarkers to predict patients` outcomes. Targeting glycolysis could be considered as a promising treatment option in BTC [49,50,51].

Nevertheless, some limitations in the present study should be acknowledged. Firstly, all included investigations were retrospective cohort studies with a small sample size and a modest level of evidence. Moreover, most participants in these studies were from Asian countries (e.g., Korea and Japan), which may be restricted to other regions. In addition, the cut-off value of interested parameters in each study was inconsistent, which needs further exploration of standard and optimal values for clinical practice. Besides, the included studies about some parameters (i.e., TLG, MTV,ΔSUVmax and LN SUVmax) were insufficient. Lastly, several HRs and their 95% CIs were extracted from univariate analysis, which might lead to an overestimation of the prognostic value of these markers.

Conclusion

In conclusion, this study demonstrated that 18F FDG PET parameters are associated with the risk of death. Especially SUVmax, TLG, MTV, and ΔSUVmax perform well in BTC patients` future survival analysis. Despite some limitations, we confirmed that 18F FDG PET could be a valuable method to help predict survival outcomes in biliary cancer patients.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

18F FDG PET:

18F-fluorodeoxyglucose positron-emission tomography

TLG:

Total lesion glycolysis

MTV:

Metabolic tumor volume

SUVmax:

Maximum Standardized uptake value

ΔSUVmax:

Change of maximum Standardized uptake value

BTC:

Biliary tract cancer

ICC:

Intrahepatic cholangiocarcinoma

ECC:

Extrahepatic cholangiocarcinoma

LN:

Lymph node

OS:

Overall survival

DFS:

Disease-free survival

PFS:

Progression-free survival

HR:

Hazard ratio

CIs:

Confidence intervals

PD-L1:

Programmed cell death ligand 1

GLUT1:

Glucose transporter 1

References

  1. Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet. 2021;397(10272):428–44.

    Article  CAS  PubMed  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  3. Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;15(5):527–36.

    Article  CAS  PubMed  Google Scholar 

  4. Cillo U, Fondevila C, Donadon M, et al. Surgery for cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):143–55.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zou H, Zhao Y. 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection: a meta-analysis. Surg Oncol. 2013;22(3):162–6.

    Article  PubMed  Google Scholar 

  6. Zhu D, Wang L, Zhang H, et al. Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(33):e7813.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Christensen TN, Andersen PK, Langer SW, et al. Prognostic value of (18)F-FDG-PET parameters in patients with small cell lung Cancer: a Meta-Analysis and Review of Current Literature. Diagnostics (Basel). 2021;11(2).

  8. Seo S, Yoh T, Morino K, et al. The relationship between (18)F-FDG uptake on PET/CT and markers of systemic inflammatory response in patients undergoing surgery for intrahepatic cholangiocarcinoma. Anticancer Res. 2019;39(1):341–6.

    Article  CAS  PubMed  Google Scholar 

  9. Yoh T, Seo S, Morino K, et al. Reappraisal of prognostic impact of tumor SUVmax by (18)F-FDG-PET/CT in intrahepatic cholangiocarcinoma. World J Surg. 2019;43(5):1323–31.

    Article  PubMed  Google Scholar 

  10. Lee EJ, Chang SH, Lee TY, et al. Prognostic value of FDG-PET/CT Total lesion glycolysis for patients with Resectable distal bile duct adenocarcinoma. Anticancer Res. 2015;35(12):6985–91.

    CAS  PubMed  Google Scholar 

  11. Kubo M, Kobayashi S, Gotoh K, et al. Preoperative FDG-positive lymph nodes predict the postoperative prognosis in Resectable biliary tract cancers. Ann Surg Oncol. 2022;29(2):935–44.

    Article  PubMed  Google Scholar 

  12. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cho KM, Oh DY, Kim TY, et al. Metabolic characteristics of advanced biliary tract Cancer using 18F-Fluorodeoxyglucose positron emission tomography and their clinical implications. Oncologist. 2015;20(8):926–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Furukawa H, Ikuma H, Asakura K, et al. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol. 2009;100(6):494–9.

    Article  PubMed  Google Scholar 

  15. Harimoto N, Hoshino K, Muranushi R, et al. Impact of metabolic parameters of (18)F-Fluorodeoxyglucose positron-emission tomography after hepatic resection in patients with intrahepatic cholangiocarcinoma. Anticancer Res. 2019;39(2):971–7.

    Article  CAS  PubMed  Google Scholar 

  16. Haug AR, Heinemann V, Bruns CJ, et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2011;38(6):1037–45.

    Article  CAS  PubMed  Google Scholar 

  17. Hwang JP, Moon JH, Kim HK, et al. Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: a STROBE study. Medicine (Baltimore). 2021;100(21):e26015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kim NH, Lee SR, Kim YH, et al. Diagnostic performance and prognostic relevance of FDG positron emission tomography/computed tomography for patients with extrahepatic cholangiocarcinoma. Korean J Radiol. 2020;21(12):1355–66.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kitamura K, Hatano E, Higashi T, et al. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer. J Hepatobiliary Pancreat Sci. 2011;18(1):39–46.

    Article  PubMed  Google Scholar 

  20. Kobayashi S, Nagano H, Hoshino H, et al. Diagnostic value of FDG-PET for lymph node metastasis and outcome of surgery for biliary cancer. J Surg Oncol. 2011;103(3):223–9.

    Article  PubMed  Google Scholar 

  21. Lee JY, Kim HJ, Yim SH, et al. Primary tumor maximum standardized uptake value measured on 18F-fluorodeoxyglucose positron emission tomography-computed tomography is a prognostic value for survival in bile duct and gallbladder cancer. Korean J Gastroenterol. 2013;62(4):227–33.

    Article  PubMed  Google Scholar 

  22. Lee Y, Yoo IR, Boo SH, et al. The role of F-18 FDG PET/CT in intrahepatic cholangiocarcinoma. Nucl Med Mol Imaging. 2017;51(1):69–78.

    Article  CAS  PubMed  Google Scholar 

  23. Levillain H, Duran Derijckere I, Ameye L, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019;46(11):2270–9.

    Article  PubMed  Google Scholar 

  24. Pak K, Kim SJ, Kim IJ, et al. Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma. Nuklearmedizin. 2014;53(2):26–31.

    Article  CAS  PubMed  Google Scholar 

  25. Park MS, Lee SM. Preoperative 18F-FDG PET-CT maximum standardized uptake value predicts recurrence of biliary tract cancer. Anticancer Res. 2014;34(5):2551–4.

    PubMed  Google Scholar 

  26. Sabaté-Llobera A, Gràcia-Sánchez L, Reynés-Llompart G, et al. Differences on metabolic behavior between intra and extrahepatic cholangiocarcinomas at (18)F-FDG-PET/CT: prognostic implication of metabolic parameters and tumor markers. Clin Transl Oncol. 2019;21(3):324–33.

    Article  PubMed  Google Scholar 

  27. Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery. 2008;143(6):769–77.

    Article  PubMed  Google Scholar 

  28. Yi HK, Park YJ, Bae JH, et al. Inverse prognostic relationships of (18)F-FDG PET/CT metabolic parameters in patients with distal bile duct Cancer undergoing curative surgery. Nucl Med Mol Imaging. 2018;52(5):334–41.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Choi MK, Choi JY, Lee J, et al. Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib. Med Oncol. 2014;31(7):23.

    Article  PubMed  Google Scholar 

  30. Jo J, Kwon HW, Park S, et al. Prospective evaluation of the clinical implications of the tumor metabolism and chemotherapy-related changes in advanced biliary tract Cancer. J Nucl Med. 2017;58(8):1255–61.

    Article  CAS  PubMed  Google Scholar 

  31. Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54.

    Article  CAS  PubMed  Google Scholar 

  32. Wardell CP, Fujita M, Yamada T, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68(5):959–69.

    Article  CAS  PubMed  Google Scholar 

  33. Parida GK, Panda RA, Agrawal K. Impact of fluorine-18-fluorodeoxyglucose PET/computed tomography in staging of patients with gallbladder cancer: a systematic review and meta-analysis. Nucl Med Commun. 2021;42(8):846–54.

    Article  CAS  PubMed  Google Scholar 

  34. Hu JH, Tang JH, Lin CH, et al. Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis. J Investig Med. 2018;66(1):52–61.

    Article  PubMed  Google Scholar 

  35. Huang X, Yang J, Li J, et al. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: a meta-analysis. Medicine (Baltimore). 2020;99(35):e20932.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kadota K, Kachala SS, Nitadori J, et al. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology. J Thorac Oncol. 2012;7(7):1192–7.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Sun XY, Chen TX, Chang C, et al. SUVmax of (18) FDG PET/CT predicts histological grade of lung adenocarcinoma. Acad Radiol. 2021;28(1):49–57.

    Article  PubMed  Google Scholar 

  38. Kasahara N, Kaira K, Bao P, et al. Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer. 2018;119:71–7.

    Article  PubMed  Google Scholar 

  39. Kasahara N, Kaira K, Yamaguchi K, et al. Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer. Lung Cancer. 2019;134:180–6.

    Article  PubMed  Google Scholar 

  40. Groves AM, Shastry M, Rodriguez-Justo M, et al. 18 F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(1):46–52.

    Article  CAS  PubMed  Google Scholar 

  41. Kaymak ZA, Karahan N, Erdoğan M, et al. Correlation of (18)F-FDG/PET SUV (max), SUV (mean), MTV, and TLG with HIF-1α in patients with colorectal Cancer. Mol Imaging Radionucl Ther. 2021;30(2):93–100.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Imai H, Kaira K, Hashimoto K, et al. Tumor immunity is related to (18) F-FDG uptake in thymic epithelial tumor. Cancer Med. 2021;10(18):6317–26.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Pant K, Richard S, Peixoto E, Gradilone SA. Role of glucose metabolism reprogramming in the pathogenesis of cholangiocarcinoma. Front Med (Lausanne). 2020;7:113.

    Article  PubMed  Google Scholar 

  44. Raggi C, Taddei ML, Rae C, et al. Metabolic reprogramming in cholangiocarcinoma. J Hepatol. 2022;77(3):849–64.

    Article  CAS  PubMed  Google Scholar 

  45. Fu K, Yang X, Wu H, et al. Diabetes and PKM2 affect prognosis in patients with intrahepatic cholangiocarcinoma. Oncol Lett. 2020;20(5):265.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Qian Z, Hu W, LV Z, et al. PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma. Clin Res Hepatol Gastroenterol. 2020;44(2):162–73.

    Article  CAS  PubMed  Google Scholar 

  47. Li X, Yu C, Luo Y, et al. Aldolase A enhances intrahepatic cholangiocarcinoma proliferation and invasion through promoting glycolysis. Int J Biol Sci. 2021;17(7):1782–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Thonsri U, Seubwai W, Waraasawapati S, et al. Overexpression of lactate dehydrogenase A in cholangiocarcinoma is correlated with poor prognosis. Histol Histopathol. 2017;32(5):503–10.

    CAS  PubMed  Google Scholar 

  49. Cai J A-O, Cui Z, Zhou J, et al. METTL3 promotes glycolysis and cholangiocarcinoma progression by mediating the m6A modification of AKR1B10. Cancer Cell Int. 2022;22(1):385.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Li L, Wang C, Qiu Z, et al. Triptolide inhibits intrahepatic cholangiocarcinoma growth by suppressing glycolysis via the AKT/mTOR pathway. Phytomedicine. 2023;109:154575.

  51. Lu S, Ke S, Wang C, et al. NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis. Oncogenesis. 2022;11(1):39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

1. National Natural Science Foundation of China (NO. 82204800).

2. Jiangsu Provincial Medical Key Discipline (Laboratory) (N0. ZDXYS202208–3).

Author information

Author notes

  1. Xia Zheng and Yue Shi share the first authorship.

Authors and Affiliations

  1. Oncology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province, No.155 Hanzhong Avenue, Nanjing, 210000, China

    Xia Zheng, Delida Kulabieke, Zihao Wang, Ying Cheng & Jun Qian

  2. Dermatology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province, No.155 Hanzhong Avenue, Nanjing, 210000, China

    Yue Shi

Authors
  1. Xia Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yue Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Delida Kulabieke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zihao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ying Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Zheng Xia and Shi Yue conceived and designed the study. Cheng Ying and Kulabieke Delida helped searched database, selected studies, extracted data. Wang Zihao preformed statistical analysis. Zheng Xia and Shi Yue wrote the draft of the manuscript. Jun Qian reviewed and edited the final manuscript critically for vital intellectual content. All authors read and approved the manuscript.

Corresponding author

Correspondence to Jun Qian.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zheng, X., Shi, Y., Kulabieke, D. et al. Prognostic significance of 18F-Fluorodeoxyglucose positron-emission tomography parameters in patients with biliary tract cancers: a meta-analysis. BMC Med Imaging 24, 9 (2024). https://doi.org/10.1186/s12880-023-01182-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12880-023-01182-4

Keywords

BMC Medical Imaging

ISSN: 1471-2342

Contact us